The Patient-Centric Approach in Health Economics

By HEOR Staff Writer

January 24, 2024

Patient-centric approach in HEOR

A Paradigm Shift in Health Economics and Outcomes Research

HEOR, which refers to health economics and outcomes research, is a realm that is difficult to navigate due to its complexity, diverse nature, and numerous facets. Nevertheless, there is one key element that stands out: the patient is the most important element. With the purpose of shedding light on the influence that this trend has on healthcare systems around the world, this article investigates the increased emphasis on a patient-centric approach in HEOR.

The Core of Health and Education

At its core, HEOR is a multidisciplinary field that aims to enhance the accessibility, fairness, and efficiency of healthcare systems for patients. It requires an understanding and appreciation of factors that significantly affect patients’ health and their experiences. This field prioritises what truly matters to patients.

The Importance of ISPOR in the Support of Patient-Centred Patient Care

Rob Abbott, as the CEO and Executive Director of The International Society for Pharmacoeconomics and Outcomes Research (ISPOR), emphasised the importance of encouraging patient-focused work. He defined this as a collaborative and meaningful interaction between patients and researchers, occurring throughout the entire research process. During the decision-making process, patient experiences, values, and expertise serve as guiding principles. This helps to ensure that the data collected ultimately contributes to the improvement of patient outcomes.

Progress and Obstacles

Significant progress has been made in centering patients in HEOR, but much work remains. We need to boost the patient’s voice and create a more patient-focused decision-making process. However, integrating the patient throughout the entire healthcare journey presents significant challenges. 

Regarding the Future Strategy of ISPOR and the Function of HEOR

As ISPOR moves on with a new plan for the year 2024, it is making concerted efforts to establish HEOR as a crucial instrument for addressing the most significant challenges in the field of global healthcare. Affordability, the impact of the rapid digitalisation of health care, and the increased desire in providing comprehensive health care are some of these factors. The patient, on the other hand, is the focal point of each and every one of these issues.

Concluding remarks

When it comes to HEOR, the patient-centric approach focuses not only on improving people’s health but also on improving the patient experience in situations where their health has been compromised. In this context, it refers to making sure that the patients’ voices are heard and that their requirements are addressed.

Reference url

Recent Posts

Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...
pharmaceutical innovation ROI
Shifting Perspectives on Pharmaceutical Innovation ROI as Socioeconomic Investment

By João L. Carapinha

June 24, 2026

Pharmaceutical innovation ROI is shifting from a narrow budget metric to a powerful indicator of societal return. Between 2014 and 2024, a 3.1-year rise in utilization-weighted mean drug vintage across 29 European countries prevented 1.83 million years of life lost before age 85 and saved 20.9 mi...
CAR T-Cell Therapy
Pioneering CAR T-Cell Therapy for Advanced Gastric Cancer

By João L. Carapinha

June 24, 2026

CAR T-Cell Therapy has reached a historic milestone with the approval of satri-cel, the world’s first authorized CAR T treatment for any solid tumor. The therapy targets Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after at l...